AI
ByCan Localized Manufacturing Shield Big Pharma from Trade Volatility? Novartis Targets Zero U.S. Tariff Exposure by Mid-2026
23 January 2026 Executive Summary Novartis CEO Vas Narasimhan has outlined a decisive trade-risk mitigation strategy, stating that…
Is U.S. Manufacturing the Next Growth Hedge for Big Pharma? Novartis Commits $23 Billion to Domestic Expansion
23 January 2026 Executive Summary Novartis has unveiled a $23 billion investment plan to significantly expand its U.S.…
Can AI Become the Backbone of Global Health Equity? Gates Foundation and OpenAI Launch $50 Million Horizon1000 Initiative in Africa
Executive Summary The Bill & Melinda Gates Foundation and OpenAI have announced a $50 million public–private initiative, Horizon1000,…
Is AI Becoming Big Pharma’s Frontline Tool for Early Cancer Detection? Bristol Myers Squibb and Microsoft Signal a Strategic Shift
Executive Summary Bristol Myers Squibb (BMS) has entered a strategic partnership with Microsoft to advance AI-driven early detection…
Can Johnson & Johnson Hit $100 Billion in Revenue Despite U.S. Pricing Pressures?
23 January 2026 Executive Summary Johnson & Johnson (J&J) has issued a bullish 2026 revenue forecast, projecting nearly…
Can AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug Discovery?
23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex, initiating a strategic…
